| Lupus erythematosus |
SLE: reduced circulating pDCs3,11-13
|
| |
DL: large amounts of IFN-α producing pDCs3,11-13
|
| |
SAL, DL: superficial distribution3
|
| |
TL, MHR: distribution around deep vessels3
|
| |
pDCs localized preferably in the epidermis in patients with DM and in the dermis in cases of lupus11
|
| Lichen planus |
pDCs arranged similarly to the band-like lymphocytic infiltrate at the dermo-epidermal junction16,17
|
| |
pDCs increased in oral lichen planus18
|
| Lichen striatus |
pDCs present in the inflammatoryinfiltrate |
| |
Perieccrine distribution of pDCs19
|
| Atopic dermatitis |
Increased circulating pDCs compared to controls |
| |
Lower recruitment of pDCs in AD lesions compared to other dermatoses, such as lupus erythematosus and psoriasis20,21
|
| Polymorphic light eruption |
Wackernagel et al.:22 absent pDCs |
| |
Rossi et al.:23 increased pDCs in PLE lesions, mainly dermal. The authors attribute the difference to the methodology witch included of a photoprovocation testing. |
| Psoriasis |
pDCs present in the T lymphocyte infiltrate in the dermis of psoriatic plaques and in the perilesional skin24
|
| |
Reduction of pDCs in the peripheral blood of patients with psoriasis24
|
| |
Heliotherapy: reduction of pDCs amount and MxA expression25
|
| |
Strong chemerin expression and presence of pDCs in the perilesional skin dermis26
|
| Pityriasis lichenoides |
Strong MxA expression in PL lesions (local production of type 1 IFN)27,28
|
| |
Presence of pDCs on the skin in all cases (PLEVA and PLC)29
|
| Graft vs. host disease |
Presence of pDCs in skin fragments of patients with acute GVHD, strong expression of MxA, signaling local production of type 1 IFN30
|
| |
Reduction of serum pDCs in patients with acute GVHD31
|
| |
Presence of CD123+ cells in the oral mucosa of patients with chronic GVHD was not superior32
|
| Warts |
Saadeh et al.:33 activated pDCs in inflamed viral warts, contrary to what was found by Tomasini et al.3 (possible differences in histologic criteria for inflamed warts). |
| |
Reduction in pDCs in peripheral blood and in skin lesions, absence of type 1 IFN production (MxA without expression) in patients with WHIM syndrome34
|
| Fungal diseases |
pDCs found in 37% of the skin fragments of patients with CBM and in 50% of the specimens from patients with PCM, but absent in cases of lobomycosis35
|
| Leprosy |
Massone et al.:36 absence of CD123 expression, except for focal expression in two cases of erythema nodosum leprosum |
| |
Hirai et al.:37 pDCs in the inflammatory infiltrate and around the vessels. Higher number of pDCs in tuberculoid cases compared to virchowian cases. |
| Skin tumors |
Keratoacanthoma: presence of pDCs in 100% of cases38
|
| |
SCC: presence of pDCs in 90% of cases38
|
| |
AK: correlation between the amount of pDCs recruited in the lesions during treatment with imiquimod and the therapeutic effect of the drug40
|
| |
BCC: presence of activated pDCs producing IFN-α in the peritumoral infiltrate during treatment with imiquimod41
|
| |
Melanoma: pDCs arranged around the vessels and close to the tumor cells, but not activated. Presence associated with tumor growth. pDCs activated in cases of regressive melanoma42
|
| |
KS: pDCs present in 90% of cases, but reduced expression of MxA (possible suppression of pDCs by KSHV)43
|